NCT07522476 is a Phase 2 clinical trial of VG2025 in Intrahepatic Cholangiocarcinoma, sponsored by Virogin Biotech Ltd..

Who is sponsoring NCT07522476?

NCT07522476 is sponsored by Virogin Biotech Ltd..

What drugs are being tested in NCT07522476?

Interventions in NCT07522476: VG2025.

What condition does NCT07522476 study?

NCT07522476 studies Intrahepatic Cholangiocarcinoma.

Is NCT07522476 still recruiting?

NCT07522476 is currently not yet recruiting. Last updated 13 April 2026.

Last reviewed 2026-04-13 · How we verify

NCT07522476

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Clinical Study to Evaluate the Efficacy and Safety of VG2025 in Intrahepatic Cholangiocarcinoma

Not yet recruiting Phase 2 Last updated 13 April 2026

What this trial tests

Phase 2 trial testing VG2025 in Intrahepatic Cholangiocarcinoma in 30 participants. Not yet recruiting.

Timeline

1 July 2026

Primary endpoint
18 January 2028

13 November 2028

Quick facts

Lead sponsor	Virogin Biotech Ltd.
Phase	Phase 2
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	1 July 2026
Primary completion	18 January 2028
Estimated completion	13 November 2028
Sites	1 location across China

Drugs / interventions tested

VG2025 — full drug profile →

Conditions studied

Intrahepatic Cholangiocarcinoma — all drugs for Intrahepatic Cholangiocarcinoma →

Sponsor

Virogin Biotech Ltd.

Who can join

Adults 18 to 75, any sex, with Intrahepatic Cholangiocarcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

VG2025 is a Recombinant Human IL12/15 Dual-Regulated Oncolytic HSV-1 Injection. Currently, one phase I dose escalation safety study has been completed in China and the United States respectively, both demonstrating excellent safety profiles with no dose-limiting toxicities (DLTs) observed and no maximum tolerated dose (MTD) identified. Moreover, it has shown preliminary efficacy in treating advanced tumors. Considering the actual clinical needs and the volume of intratumoral administration, a more appropriate recommended phase 2 dose (RP2D) level has been selected for the phase II clinical trial.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of VG2025

Trials testing the same drug.

NCT07357220 — A Study of AK112 in Combination With VG2025 in Colorectal Cancer With Liver Metastases · Phase 1, PHASE2 · not yet recruiting
NCT06365918 — Study of VG2025 Delivered Intraperitoneally in Patients With Advanced Solid Tumors With Carcinomatosis · Phase 1 · withdrawn
NCT05266612 — Phase I Study VG2025 as a Single Agent and in Combination Therapy With Nivolumab in Subjects With Advanced Malignant Sol · Phase 1 · recruiting

Other recruiting trials for Intrahepatic Cholangiocarcinoma

Currently open trials in the same condition.

NCT06990659 — Outpatient Versus Inpatient Care Pathway for Intra-arterial Treatment of Primary Liver Cancer (CHOC) · NA · recruiting
NCT06910722 — Liver Transplantation for Locally Advanced Intrahepatic Cholangiocarcinoma After SIRT and Chemotherapy · NA · recruiting
NCT07169734 — A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors · Phase 1, PHASE2 · recruiting
NCT06664021 — Exploring the Efficacy and Safety of Tislelizumab in Combination With S-1 in the Treatment of Patients With Postoperativ · Phase 2 · recruiting
NCT06505486 — GEMOX-HAIC Plus GEM-SYS in Combination With Lenvatinib and PD-1 Inhibitor for Large Unresectable ICC · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07522476 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Virogin Biotech Ltd.
Last refreshed: 13 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07522476.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing